Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Abroad (travel likely)RecruitingPHASE2
Conditions
Chronic Myeloid Leukemia (CML)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Novartis Investigative Site, Bordeaux, France
Novartis Investigative Site, Lille, France
Novartis Investigative Site, Lyon, France
Novartis Investigative Site, Nantes, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Vandœuvre-lès-Nancy, France
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals